Introduction To evaluate effects of Ocufolin on retinal microvasculature in mild non-proliferative diabetic retinopathy patients who carried methylenetetrahydrofolate reductase (MTHFR) polymorphisms (DR+MTHFRP). Research design and methods This is a prospective cohort study. Eight DR+MTHFRP (administrated Ocufolin for 6 months) and 15 normal controls (NCs) were recruited. MTHFR polymorphisms were subtyped as normal, C677T, or A1298C. Best-corrected visual acuity (BCVA) was evaluated. Retinal vessel density (VD) and microstructure were evaluated by optical coherence tomography angiography. Results BCVA and vascular indices of DR+MTHFRP at baseline were worse than those of NC and improved. Compared with baseline, DR+MTHFRP had significantly improved BCVA during follow-up period (p<0.05). VD of superficial vascular plexus was increased at 4 months (p=0.012), while VD of retinal vascular network did not change (p>0.05). Carriers of A1298C and C677T showed statistically significant increase in VD at all layers by 6 months, while carriers of C677T alone showed no significant change and carriers of A1298C alone showed decreased density from 4 months to 6 months. Microstructure did not change during the follow-up period. Conclusion A 6-month intake of Ocufolin is capable of reversing structural changes of microangiopathy in mild non-proliferative DR+MTHFRP. This suggests a novel way to address these impairments prior to catastrophic vision loss. Data are available in a public, open access repository. JW had full access to all data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

中文翻译：

---

Ocufolin对携带MTHFR基因多态性的轻度非增殖性糖尿病视网膜病变患者视网膜微血管系统的影响

简介 评估 Ocufolin 对携带亚甲基四氢叶酸还原酶 (MTHFR) 多态性 (DR+MTHFRP) 的轻度非增殖性糖尿病视网膜病变患者视网膜微血管系统的影响。研究设计和方法 这是一项前瞻性队列研究。招募了 8 名 DR+MTHFRP（给予 Ocufolin 6 个月）和 15 名正常对照 (NC)。MTHFR 多态性被分为正常、C677T 或 A1298C 亚型。评估了最佳矫正视力（BCVA）。通过光学相干断层扫描血管造影术评估视网膜血管密度（VD）和显微结构。结果 DR+MTHFRP基线BCVA和血管指标较NC差，但有所改善。与基线相比，DR+MTHFRP 在随访期间显着改善了 BCVA（p<0.05）。4个月时浅层血管丛VD增加（p=0.012），而视网膜血管网VD无变化（p>0.05）。A1298C 和 C677T 的载体在 6 个月时所有层的 VD 都有统计学意义的增加，而单独的 C677T 载体没有显着变化，单独的 A1298C 载体的密度从 4 个月降低到 6 个月。随访期间显微组织未发生变化。结论 服用 6 个月的 Ocufolin 能够逆转轻度非增殖性 DR+MTHFRP 微血管病变的结构变化。这提出了一种在灾难性视力丧失之前解决这些损伤的新方法。数据可在公共、开放访问的存储库中获得。